The LRRK2-14-3-3 interaction network is a critical regulatory mechanism controlling Leucine-Rich Repeat Kinase 2 (LRRK2) subcellular localization, kinase activity, and pathogenic signaling in Parkinson's disease (PD). The 14-3-3 protein family (especially ζ, β, η, and θ isoforms) directly binds to phosphorylated LRRK2, sequestering it in the cytoplasm and regulating its function.
This network sits at the intersection of LRRK2 biology and Parkinson's disease pathogenesis. Pathogenic LRRK2 mutations (including the common G2019S variant) disrupt the 14-3-3 interaction, leading to constitutive kinase activation and pathogenic signaling. Understanding this regulatory mechanism provides essential insights for developing therapeutic strategies targeting LRRK2.
¶ Structure and Domains
LRRK2 is a large 2527-amino acid protein belonging to the leucine-rich repeat kinase family:
N-terminal regions:
- Armadillo repeats (12-330): Protein-protein interactions
- Ankyrin repeats (331-500): Additional interaction surfaces
Leucine-rich repeat (LRR) domain (500-680):
- N-terminal LRR portion
- Protein substrate recognition
- Dimerization interface
Kinase domain (1277-1512):
- Catalytic serine/threonine kinase activity
- Autophosphorylation sites
- Target of most LRRK2 inhibitors
ROC GTPase domain (1513-1700):
- Ras of complex proteins domain
- GTP/GDP binding
- Regulates kinase activity through intramolecular interactions
COR domain (1701-1847):
- C-terminal of ROC
- Mediates homodimerization
- Communication between ROC and kinase domains
WD40 repeat domain (1877-2099):
- Beta-propeller fold
- Protein-protein interactions
- Membrane localization signals
LRRK2 functions as a serine/threonine kinase with multiple autophosphorylation sites:
Key autophosphorylation sites:
- Ser1292: Major autophosphorylation site, 14-3-3 binding
- Ser973: ROC domain
- Ser935: Regulatory site, 14-3-3 binding
Substrate phosphorylation:
- Rab proteins (Rab3A, Rab8A, Rab10, Rab12, Rab35)
- Modulates autophagy and vesicular trafficking
- Pathogenic signaling through substrate phosphorylation
LRRK2 mutations are the most common genetic cause of familial PD:
| Mutation |
Domain |
Effect |
Prevalence |
| G2019S |
Kinase |
Increased kinase activity |
~1-5% familial PD |
| R1441C/G/H |
ROC |
Reduced GTPase activity |
~3-7% familial PD |
| N1437H |
ROC |
Reduced GTPase activity |
~1% familial PD |
| I2020T |
Kinase |
Increased kinase activity |
Japanese families |
| G2019S is the most common pathogenic variant, increasing kinase activity by approximately 2-3 fold. |
|
|
|
The 14-3-3 protein family consists of seven conserved isoforms in mammals[jensen2020]:
Structural features:
- Homo- and heterodimeric proteins
- Amphipathic groove for phospho-Ser/Thr binding
- Highly conserved across eukaryotes
Brain-expressed isoforms:
- 14-3-3ζ (YWHAZ): Most studied in LRRK2 regulation
- 14-3-3β (YWHAB): Highly expressed in neurons
- 14-3-3η (YWHAH): Brain-enriched isoform
- 14-3-3θ (YWHAQ): T-cell enriched
14-3-3 proteins function as molecular scaffolds:
Phospho-Ser/Thr binding:
- Recognition motif: RSXpS/TXP or RXXXpS/TXP
- Binds phosphorylated serine/threonine residues
- Conformational recognition
Subcellular localization:
- Cytoplasmic sequestration
- Nuclear import/export regulation
- Membrane targeting
Protein stabilization:
- Protects against dephosphorylation
- Prevents protein degradation
- Maintains signaling complexes
LRRK2 phosphorylation at Ser1292 creates the 14-3-3 binding site[zhao2022]:
Ser1292 phosphorylation:
- Autophosphorylation by LRRK2 kinase domain
- Casein kinase 2 (CK2) can also phosphorylate this site
- Critical for 14-3-3 interaction
14-3-3 binding mode:
- 14-3-3 dimer binds phosphorylated LRRK2
- Simultaneous binding to two phospho-sites
- Stable cytoplasmic complex
The LRRK2-14-3-3 structure reveals[cook2019]:
Binding interface:
- Phospho-Ser1292 fits into 14-3-3 amphipathic groove
- Additional contacts stabilize the complex
- Dimeric 14-3-3 bridges LRRK2 regions
Complex stability:
- Phosphorylation required for binding
- Dephosphorylation disrupts interaction
- Dynamic regulation
The primary function of 14-3-3 binding is cytoplasmic retention:
Mechanism:
- 14-3-3-LRRK2 complex remains in cytoplasm
- Membrane recruitment is blocked
- Kinase activity is modulated
Consequences:
- Prevents LRRK2 from reaching membranes
- Limits substrate access
- Reduces pathogenic signaling
Cellular stress modulates the interaction:
Stress triggers:
- Mitochondrial toxins: Increase LRRK2 membrane localization
- Oxidative stress: Modifies 14-3-3 binding
- Nutrient deprivation: Activates LRRK2
Dephosphorylation:
- Protein phosphatases can dephosphorylate Ser1292
- Releases LRRK2 from 14-3-3
- Allows membrane targeting
Disease mutations disrupt the 14-3-3 interaction[davies2023]:
G2019S mutation:
- Increases autophosphorylation at some sites
- Reduces Ser1292 phosphorylation
- Weakens 14-3-3 binding
- Results in constitutive kinase activity
R1441C/G/H mutations:
- Affect ROC GTPase domain
- Impair GTPase activity
- Alter 14-3-3 binding indirectly
- Constitutive activation
flowchart TD
subgraph Normal_Regulation
CK2["CK2"] -->|"phosphorylates"| Ser1292["LRRK2<br/>Ser1292"]
Ser1292 -->|"binds"| 14-3-3["14-3-3<br/>Dimer"]
14-3-3 -->|"sequesters"| Cytoplasm["Cytoplasm"]
end
subgraph Activation_Trigger
Stress["Cellular<br/>Stress"] -->|"activates"| Phosphatase["Phosphatase"]
Phosphatase -->|"dephosphorylates"| Ser1292
end
subgraph Membrane_Localization
Ser1292 -.->|"dissociates"| 14-3-3
14-3-3 -->|"releases"| LRRK2_Free["Free LRRK2"]
LRRK2_Free -->|"translocates"| Membrane["Membrane"]
Membrane -->|"autophosphorylates"| Active_LRRK2["Active<br/>LRRK2"]
end
subgraph Pathogenic_Mutation
G2019S["G2019S<br/>Mutation"] -->|"reduces"| P_Ser1292["Phospho-Ser1292"]
P_Ser1292 -.->|"weakens"| 14-3-3_Binding["14-3-3 Binding"]
14-3-3_Binding -->|"constitutive"| Hyperactive["Hyperactive<br/>LRRK2"]
end
subgraph Signaling_Output
Active_LRRK2 -->|"phosphorylates"| Rab["Rab<br/>GTPases"]
Rab -->|"regulates"| Autophagy["Autophagy"]
Rab -->|"regulates"| Vesicles["Vesicle<br/>Trafficking"]
Hyperactive -->|"causes"| PD_Pathology["Parkinsonian<br/>Pathology"]
end
style 14-3-3 fill:#c8e6c9,stroke:#333
style Active_LRRK2 fill:#ff9,stroke:#333
style Hyperactive fill:#ffcdd2,stroke:#333
LRRK2 phosphorylation of Rab proteins modulates autophagy[schapansky2018]:
Rab targets:
- Rab8A, Rab10: Primary LRRK2 substrates
- Rab12, Rab35: Additional substrates
- Rab29: Regulates LRRK2 recruitment to lysosomes
Autophagy effects:
- Phagophore formation
- Autophagosome maturation
- Lysosomal fusion
LRRK2 regulates vesicular trafficking:
Synaptic function:
- Synaptic vesicle cycling
- Neurotransmitter release
- Presynaptic terminal maintenance
Endosomal trafficking:
- Endosomal sorting
- Lysosomal delivery
- Membrane protein recycling
LRRK2 targets to various membranes:
Cellular membranes:
- Lysosomal membrane
- Endoplasmic reticulum
- Synaptic vesicles
Membrane targeting:
- WD40 domain mediates targeting
- Palmitoylation can regulate
- Lipid interactions important
Therapeutic strategies to enhance 14-3-3 binding:
Kinase inhibitors:
- CK2 inhibitors: Increase Ser1292 phosphorylation
- Indirect enhancement of 14-3-3 binding
Stabilizing compounds:
- Small molecules enhancing the interaction
- Peptide mimetics of binding motifs
- Protein-protein interaction stabilizers
The primary therapeutic approach[marchand2022]:
| Compound |
Company |
Stage |
Notes |
| DNL151 |
Denali |
Phase II |
Brain-penetrant |
| BIIB122 |
Biogen/Denali |
Phase I |
New formulation |
| PF-06447475 |
Pfizer |
Preclinical |
Neuroprotective |
| GLP-1 |
Various |
Various |
May reduce LRRK2 |
Clinical considerations:
- Kinase selectivity important
- Brain penetration required
- Long-term safety concerns
Rational combinations for PD:
- LRRK2 inhibitor + 14-3-3 stabilizer: Multi-target
- Kinase inhibitor + autophagy enhancer: Functional enhancement
- LRRK2 inhibitor + anti-alpha-synuclein: Synergistic
LRRK2 mutations cause familial PD:
Genetic evidence:
- Autosomal dominant inheritance
- Incomplete penetrance
- Variable age of onset
Pathology:
- Lewy body pathology in some cases
- Tau pathology in others
- Variable neuropathology
LRK2 associations beyond PD:
- Inflammatory disease: LRRK2 in Crohn's disease
- Cancer: LRRK2 in various cancers
- Infection: LRRK2 in bacterial defense
The LRRK2-14-3-3 network connects to multiple PD-related mechanisms:
The LRRK2-14-3-3 interaction network is a critical regulatory mechanism controlling LRRK2 localization, activity, and pathogenic signaling in Parkinson's disease. 14-3-3 proteins bind to phosphorylated LRRK2 (primarily at Ser1292), sequestering it in the cytoplasm and preventing inappropriate activation.
Pathogenic LRRK2 mutations disrupt this interaction, leading to constitutive kinase activation and neurodegeneration. The G2019S mutation, the most common genetic cause of familial PD, reduces Ser1292 phosphorylation and weakens 14-3-3 binding, resulting in hyperactive LRRK2 signaling.
Therapeutic strategies include LRRK2 kinase inhibitors (currently in clinical trials) and approaches to restore or enhance the 14-3-3 interaction. Understanding the full complexity of this regulatory network provides essential foundations for developing disease-modifying treatments for Parkinson's disease.